<?xml version="1.0" encoding="UTF-8"?>
<p id="Par33">Considering the ongoing transmission of HCV in people who inject drugs (PWID), it is important to highlight harm reduction efforts due to needle and syringe programmes and opioid substitution therapy. Moreover, DAA treatment in these populations at higher risk of contracting infection could potentially decrease transmission but decrease re-infections much more.</p>
